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ABSTRACT 
Fisetin is found in various fruits and vegetables. It is reported to have neurotropic, anti-inflammatory, anti-carcinogenic and also other health 
benefits. Fisetin has been proved to have neuroprotective effect against Parkinson’s disease (PD).  Elucidation of the molecular interaction of 
fisetin with various anti-parkinsonian drug targets leads to better understanding mode of action of the drug. The present study is aimed to study 
the molecular interaction of fisetin with molecular targets having potential role in PD. The molecular properties and drug likeness model score 
were first analysed for flavonoid fisetin, which was found to be 0.76. The structures of the molecular drug targets, such as MAO A (2BXR), MAO B 
(2BYB), COMT (2AVD) and tyrosine hydroxylase (2XSN), was extracted from RCSB-Protein Data Bank. Molecular docking was performed using 
AUTO DOCK-4.2. The docking scores were evaluated by analyzing the minimum binding energy for the first five runs for all the target proteins. 
The minimum binding energy for MAO A (2BXR), MAO B (2BYB), COMT (2AVD), tyrosine hydroxylase (2XSN) were -10.22 kcal/mol, -9.68 
kcal/mol, -7.45 kcal/mol and -6.67 kcal/mol respectively. Out of the 4 potential PD drug targets, MAO A and MAO, genes responsible for 
oxidative deamination of dopamine, are predicted to have the least minimum binding energy and best interaction with fisetin.  
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Parkinson’s disease is characterized by progressive loss of 
dopaminergic neurons in the substantia nigra, leading to the 
loss of motor skills 1-4. The key causative factors that might 
influence disease outcomes include buildup of reactive 
oxygen species (ROS), selective loss of neurons, loss of 
mitochondrial membrane potential and ATP depletion 5. 
Flavonoid, fisetin has gained great interest due to its diverse 
pharmacological effects, such as antioxidant, anti-
inflammatory, anticancer and antihypertensive action, 
among others 6. The impaired function of Parkinson disease 
can be ameliorated by using flavonoid fisetin, which has high 
antioxidative and neuroprotective activities 7. 
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The  emerging neuroprotective  therapies  are  not  effective  
due  to  restricted understanding  of  the  important  
molecular  event  that  stimulate neurodegeneration.  The 
causes PD pathogenesis is thought to be due to the 
misfolding of proteins, dysfunction mitochondria & the 
ubiquitin proteasome pathway, oxidative stress and 
deregulation dopamine metabolism 8. The major enzymes 
involved in dopamine metabolism include MAO A, MAO B, 
COMT - involved in dopamine degradation and tyrosine 
hydroxylase - involved in dopamine synthesis. The main 
objective of this study was to dock the flavonoid fisetin as 
ligand with the molecular targets of Parkinson’s disease. In 
silico methods are regularly used in modern drug design to 
help apprehend drug–target protein interactions. The results 
obtained from this study would be useful in understanding 
the mechanism of neuro-protective effect of fisetin.  
MATERIALS AND METHODS 
Preparation of the protein and Ligand Structures 
The three dimensional X–ray structure of MAO A (2BXR), 
MAO B (2BYB), COMT (2AVD), tyrosine hydroxylase (2XSN)  
was obtained from RCSB Protein Data Bank. The structure 
was refined by removing water molecules and other 
complexed molecules. Hydrogen atoms were added and 
electronic charges were assigned to the protein atoms using 
kollman united atoms force field by using AutoDockTools–
1.5.6 9. The gasteiger partial atomic charges were added and 
all possible flexible torsion angles of the ligand was defined 
by using AUTOTORS. The structures were saved in a PDBQT 
format for AutoDock calculations. 
The ligand fisetin structure was drawn using chemsketch. To 
understand the molecular interaction of fisetin, blind 
docking of fisetin onto MAO A (2BXR), MAO B (2BYB), COMT 
(2AVD) and tyrosine hydroxylase (2XSN) proteins was 
carried out. The docking calculations were carried out using 
both the Genetic Algorithm and Lamarckian Genetic 
Algorithm. 
Docking Studies and Drug likeness 
Docking calculations were performed to predict the binding 
affinity between the fisetin and MAO A (2BXR), MAO B 
(2BYB), COMT (2AVD), tyrosine hydroxylase (2XSN) proteins 
using AutoDock 4.2 10. AutoDock requires precalculated grid 
maps, one for each atom type present in the ligand being 
docked. These maps were calculated by using the auxiliary 
program AutoGrid. The compounds treated as flexible 
molecules were allowed to move in the six spatial degrees of 
freedom for orientation and torsional degrees of freedom 
within the grid box. 
AutoDock uses a semi empirical free energy force field to 
evaluate conformations during docking simulations. The 
energy functions define what contributes to the energy of the 
molecule, like bond stretching, bending etc., so that energy of 
the molecule can be calculated for any particular 
conformation. The force field evaluates binding in two steps. 
In the first step, the intramolecular energetics is estimated 
for the transition from unbound states to the conformation 
of the ligand and protein in the bound state. The second step 
then evaluates the intermolecular energetics of combining 
the ligand and protein in their bound conformation. 
ΔG = ΔGvdw + ΔGhbond + ΔGelec +ΔGtor+ ΔGdesolv 
First three terms are for van der Waal’s, hydrogen bonding, 
electrostatics respectively. The term ΔGtor is for rotation 
and translation and ΔGdesolv is for desolvation upon binding 
and the hydrophobic effect 10. Drug-Likeness and molecular 
property prediction for the fisetin was done by molsoft. 
RESULTS AND DISCUSSION 
The first best five minimum binding energy of fisetin with 
the 4 drug targets are shown in following table. 
  
Table 1: Minimum Binding Energy of fisetin with the 4 drug targets of the top hits 
2BXR: MAO A 2AVD: COMT 
S. No Run Minimum Binding Energy S. No Run Minimum Binding Energy 
1 8 -10.22 kcal/mol 1 6 -7.45 kcal/mol 
2 5 -10.07 kcal/mol 2 7 -7.36 kcal/mol 
3 10 -9.63 kcal/mol 3 8 -7.26 kcal/mol 
4 1 -9.51 kcal/mol 4 9 -7.22 kcal/mol 
5 4 -8.98 kcal/mol 5 5 -6.9 kcal/mol 
2BYB: MAO B 2XSN: tyrosine hydroxylase 
S. No Run Minimum Binding Energy S. No Run Minimum Binding Energy 
1 6 -9.68 kcal/mol 1 7 -6.67 kcal/mol 
2 7 -9.42 kcal/mol 2 6 -6.48 kcal/mol 
3 1 -9.02 kcal/mol 3 9 -6.6 kcal/mol 
4 5 -8.69 kcal/mol 4 4 -6.31 kcal/mol 
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Table 2: Lowest binding energy of fisetin with the 4 drug targets of the top hits 
S.No. Protein Final Intermolecular Energy (vdW + 








Energy   
1 MAO A -11.71 kcal/mol -1.34 kcal/mol +1.49 kcal/mol -1.34 kcal/mol 
2 MAO B -11.18 kcal/mol -1.37 kcal/mol +1.49 kcal/mol -1.37 kcal/mol 
3 COMT -8.94 kcal/mol -0.94 kcal/mol +1.49 kcal/mol -0.94 kcal/mol 
4 tyrosine 
hydroxylase 
-8.17 kcal/mol -1.63 kcal/mol +1.49 kcal/mol -1.63 kcal/mol 
 
Figure 2 shows the lowest binding energy conformation of 
fisetin with MAO, Figure 3 shows the lowest binding energy 
conformation of fisetin with MAO B. Figure 4 shows the 
lowest binding energy conformation of fisetin with COMT. 
Figure 5 shows the lowest binding energy conformation of 
fisetin with tyrosine hydroxylase. These structures are 
visualized using chimera 11. The red color denotes oxygen 
atom in the ligand fisetin and the blue and orange colored 
lines denotes the interaction between ligand and the protein 
molecules. 
 
Figure 2:  (2BXR-A: MAOA) 
 
Figure 3: (2BYB-A: MAOB) 
 
Figure 4: (2AVD-A: COMT) 
 
 
Figure 5: (2XSN-A: tyrosine hydroxylase) 
 
Drug likeness model score of fisetin was 0.76, shown in figure 
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Molecular Properties of fisetin using molsoft 
 
 
Figure 6: Drug likeness model score of fisetin 
 
CONCLUSION 
In the present study, the binding and interactions of fisetin 
with MAO A (PDB ID: 2BXR), MAO B (PDB ID: 2BYB), COMT 
(PDB ID: 2AVD) , tyrosine hydroxylase (PDB ID: 2XSN) 
proteins have been studied using molecular docking 
calculations. Fisetin has shown significant binding 
interactions with the MAO A (PDB ID: 2BXR), MAO B (PDB ID:  
2BYB), COMT (PDB ID: 2AVD), tyrosine hydroxylase (PDB ID: 
2XSN) proteins. Interrupting critical interactions of the 
biomolecules can solve the “targeted therapy crisis” problem 
in neurodegenerative diseases. Since, fisetin can interact with 
the multi-target proteins involved in the development of 
Parkinson’s disease, fisetin can be used to design novel and 
highly efficient drug for the treatment of Parkinson’s disease 
therapeutics. 
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